Chronic low-grade inflammation associated with MetS, driven by elevated levels of inflammatory cytokines (e.g., IL-6 and TNF-α), fosters a pro-tumorigenic microenvironment by activating signaling pathways like NF-κB and STAT3 (19). This evidence concerns the gene IL6 and metabolic syndrome.